ADAPTIVE BIOTECHNOLOGIES CORPORATION Financials Adaptive Biotechnologies Corporation
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 USD | -0.38% |
|
+8.33% | -46.94% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,720 | 8,087 | 3,960 | 1,093 | 709.4 | 377.2 | - | - |
| Enterprise Value (EV) 1 | 3,720 | 7,399 | 3,607 | 594.4 | 653.7 | 281 | 135.6 | 457.5 |
| P/E ratio | -29.6 x | -53.3 x | -19 x | -5.46 x | -3.14 x | -1.98 x | -2.43 x | -3.43 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 43.7 x | 82.2 x | 25.7 x | 5.9 x | 4.17 x | 2.15 x | 1.71 x | 1.31 x |
| EV / Revenue | 43.7 x | 75.2 x | 23.4 x | 3.21 x | 3.84 x | 1.6 x | 0.61 x | 1.59 x |
| EV / EBITDA | -64.7 x | -61.9 x | -23.8 x | -4.89 x | -5.62 x | -2.43 x | -3.12 x | -18.9 x |
| EV / FCF | 19.2 x | -43.9 x | -14.2 x | -2.97 x | -3.91 x | -3.43 x | -10.4 x | 18.3 x |
| FCF Yield | 5.22% | -2.28% | -7.05% | -33.7% | -25.5% | -29.2% | -9.58% | 5.46% |
| Price to Book | 3.62 x | 10.4 x | 6.57 x | 2.36 x | 2.29 x | 2.86 x | 4.87 x | 11 x |
| Nbr of stocks (in thousands) | 124,339 | 136,772 | 141,132 | 143,012 | 144,773 | 145,092 | - | - |
| Reference price 2 | 29.92 | 59.13 | 28.06 | 7.640 | 4.900 | 2.600 | 2.600 | 2.600 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/15/22 | 2/14/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 85.07 | 98.38 | 154.3 | 185.3 | 170.3 | 175.6 | 220.9 | 287 |
| EBITDA 1 | -57.48 | -119.6 | -151.7 | -121.6 | -116.4 | -115.8 | -43.49 | -24.19 |
| EBIT 1 | -78.39 | -152.8 | -209 | -200.2 | -227 | -189.7 | -146.7 | -110.9 |
| Operating Margin | -92.15% | -155.33% | -135.39% | -108.03% | -133.33% | -108.05% | -66.4% | -38.65% |
| Earnings before Tax (EBT) 1 | -68.61 | -146.2 | -207.3 | -200.4 | -225.3 | -192.8 | -144.6 | -114 |
| Net income 1 | -69.57 | -146.2 | -207.3 | -200.2 | -225.2 | -192.9 | -144.6 | -114.1 |
| Net margin | -81.78% | -148.63% | -134.3% | -108.03% | -132.29% | -109.85% | -65.46% | -39.74% |
| EPS 2 | -1.010 | -1.110 | -1.480 | -1.400 | -1.560 | -1.311 | -1.071 | -0.7578 |
| Free Cash Flow 1 | 194.2 | -168.5 | -254.5 | -200.3 | -167 | -82 | -13 | 25 |
| FCF margin | 228.28% | -171.26% | -164.87% | -108.09% | -98.09% | -46.7% | -5.89% | 8.71% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/24/21 | 2/15/22 | 2/14/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 39.47 | 37.93 | 38.62 | 43.66 | 47.83 | 55.2 | 37.65 | 48.93 | 37.92 | 45.78 | 38.78 | 43.41 | 43.22 | 50.36 | 44.44 |
| EBITDA 1 | -41.06 | -44.95 | -45.15 | -33.13 | -25.87 | -19.56 | -37.1 | -24.82 | -29.83 | -24.66 | -32.9 | -29.44 | -26.26 | -29.05 | -17.2 |
| EBIT 1 | -56.32 | -61.6 | -63.07 | -52.5 | -45.43 | -39.19 | -57.19 | -47.82 | -50.96 | -71.07 | -50.98 | -47.32 | -45.65 | -46.18 | -46.4 |
| Operating Margin | -142.71% | -162.39% | -163.3% | -120.25% | -94.98% | -70.99% | -151.92% | -97.74% | -134.38% | -155.22% | -131.47% | -109% | -105.61% | -91.7% | -104.41% |
| Earnings before Tax (EBT) 1 | -56 | -61.36 | -62.8 | -52.08 | -45.32 | -40.17 | -57.7 | -47.81 | -50.33 | -69.47 | -50.99 | -47.44 | -46.23 | -46.94 | -45.5 |
| Net income 1 | -55.9 | -61.43 | -62.74 | -52.05 | -45.28 | -40.13 | -57.7 | -47.81 | -50.3 | -69.44 | -50.99 | -47.44 | -46.23 | -46.94 | -45.5 |
| Net margin | -141.64% | -161.96% | -162.44% | -119.21% | -94.67% | -72.7% | -153.26% | -97.72% | -132.65% | -151.67% | -131.47% | -109.28% | -106.95% | -93.21% | -102.4% |
| EPS 2 | -0.4000 | -0.4300 | -0.4400 | -0.3700 | -0.3200 | -0.2800 | -0.4000 | -0.3300 | -0.3500 | -0.4800 | -0.3463 | -0.3265 | -0.3168 | -0.3168 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/15/22 | 5/4/22 | 8/3/22 | 11/3/22 | 2/14/23 | 5/3/23 | 8/2/23 | 11/9/23 | 2/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 80.2 |
| Net Cash position 1 | - | 688 | 353 | 498 | 55.7 | 96.2 | 242 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -3.316 x |
| Free Cash Flow 1 | 194 | -168 | -254 | -200 | -167 | -82 | -13 | 25 |
| ROE (net income / shareholders' equity) | -44.5% | -22.3% | -30.8% | -37.5% | -51.7% | -91.4% | -115% | -133% |
| ROA (Net income/ Total Assets) | -11.2% | -14.4% | -20.3% | -22.5% | -26.3% | -32.4% | -21.1% | -13.6% |
| Assets 1 | 622.3 | 1,014 | 1,020 | 890 | 855.4 | 594.9 | 686.6 | 841.2 |
| Book Value Per Share 2 | 8.260 | 5.660 | 4.270 | 3.240 | 2.140 | 0.9100 | 0.5300 | 0.2400 |
| Cash Flow per Share | 2.970 | -1.140 | -1.370 | -1.290 | - | - | - | - |
| Capex 1 | 11.2 | 18.8 | 61.7 | 16.3 | 10.7 | 12 | 16 | 19 |
| Capex / Sales | 13.17% | 19.11% | 40.01% | 8.82% | 6.28% | 6.83% | 7.24% | 6.62% |
| Announcement Date | 2/26/20 | 2/24/21 | 2/15/22 | 2/14/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.6
USD
Average target price
6.667
USD
Spread / Average Target
+156.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.94% | 377M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| +13.32% | 332M |
- Stock Market
- Equities
- ADPT Stock
- Financials Adaptive Biotechnologies Corporation
